Step Pharma, a developer of treatments for autoimmune diseases, has completed its series A round after closing a second tranche.
France-based autoimmune disease drug developer Step Pharma closed a series A round featuring drug development services provider Sygnature Discovery at €14.5m ($17m) yesterday.
The round was closed following an €8.6m second tranche and included research institution Imagine Institute, Kurma Partners, Inserm Transfert Initiative, Pontifax, Idinvest Partners and Fonds Biothérapies Innovantes et Maladies Rares, a vehicle for state-owned investment bank Bpifrance.
Sygnature Discovery, Bpifrance, Inserm Transfer Initiative, Imagine Institute, Kurma and Idinvest had provided the initial funding for the round in…
